Cytosorbents (CTSO) EBT Growth (1y) (2011 - 2026)
Cytosorbents (CTSO) EBT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.49 Bn | 193.88 Bn | 7.27 Bn | -29.12% |
| 2 | Stryker | 127.80 Bn | 124.32 Bn | 4.50 Bn | 53.94% |
| 3 | Medtronic | 118.98 Bn | 109.76 Bn | 6.41 Bn | 45.44% |
| 4 | Boston Scientific | 73.58 Bn | 73.04 Bn | 3.85 Bn | 12.65% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 29.89% |
| 6 | Dexcom | 34.34 Bn | 32.39 Bn | 830.00 Mn | 31.69% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.66 Bn | 2.18 Bn | 13.05% |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | 71.38% |
| 9 | Steris | 23.07 Bn | 22.59 Bn | 684.20 Mn | 17.94% |
| 10 | Cytosorbents | 21.98 Mn | 17.56 Mn | 7.05 Mn | 17.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -484.48% |
| Mar 31, 2026 | -646.77% |
| Dec 31, 2025 | -323.00% |
| Sep 30, 2025 | -29.01% |
| Jun 30, 2025 | -487.02% |
| Mar 31, 2025 | 75.72% |
| Dec 31, 2024 | 135.47% |
| Sep 30, 2024 | 69.87% |
| Jun 30, 2024 | 34.93% |
| Mar 31, 2024 | 16.85% |
| Dec 31, 2023 | -273.84% |
| Sep 30, 2023 | 24.69% |
| Jun 30, 2023 | 39.32% |
| Mar 31, 2023 | 18.33% |
| Dec 31, 2022 | 81.49% |
| Sep 30, 2022 | -90.45% |
| Jun 30, 2022 | -132.58% |
| Mar 31, 2022 | -115.13% |
| Dec 31, 2021 | -456.46% |
| Sep 30, 2021 | -662.90% |